Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome

Executive Summary

FDA, industry and patient advocates all want studies to move beyond HbA1c, but still need to develop common thresholds and definitions to support patient-reported outcomes in diabetes drug development.

You may also be interested in...



FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight

US agency's events could address a touchy subject: how much responsibility does FDA have for preventing adverse events, and how much falls to physicians?

Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials

Industry mostly using the patient-reported outcomes as exploratory endpoints.

Diabetes Trials Tend To Eschew Patient-Reported Outcomes

A Pink Sheet analysis finds that most Phase III diabetes studies are not using patient-reported outcomes, which still tend to lack standardized measurements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel